Healthcare

Growth Insights on the Global CRISPR/Cas9 Tools Market, 2017

Since its inception, CRISPR has gained strong traction from the global research community because of its huge potential in diverse applications. Considering CRISPR’s disruptive and game-changing applications, a number of large and small participants have invested in this domain. Along the same line, CRISPR has witnessed a multi-fold uptake in funding from the National Institutes of Health (NIH) and other government agencies. As a result, these investments have led to significant growth in new product and application development, thereby creating new market segments and revenue growth opportunities for existing companies and new entrants.
In 2017, the CRISPR/Cas9 tools market opportunity will likely be about $1.8 to $2 billion. The therapeutics and agriculture segments will contribute the most revenue potential. The market is currently highly fragmented, with a handful of global participants and a large number of application-focused participants operating in their respective segments. Competition in the therapeutics and agriculture domains is highly concentrated, and most market and technology developments have been focused around a few companies. Even large pharmaceutical companies have partnered with these existing participants to source innovation and to support their product development using CRISPR. With the ongoing patent war between the University of California and Broad Institute, this situation will likely remain the same. Frost & Sullivan expects that large pharmaceutical companies will only commit direct investments in this segment after understanding the final outcome of the ongoing patent cases.
The objective of this research study is to consider and analyze all these market developments and present a realistic market landscape. This research publication covers insights on existing and emerging growth opportunities in the CRISPR/Cas9 tools market. The study covers qualitative market insights on various market segments and sub-segments, including agriculture, human therapeutics, research tools, and drug discovery activities. The report identifies existing gaps in product and service offerings of key participants across segments, disruptive technologies, and key market and technology trends. The research study further delves into the market’s competitive landscape and patent licensing landscape analysis.
Key Questions This Study Will Answer:
• Who are the key competitors in the emerging CRISPR/Cas9 market, both tools and therapeutics?
• What are the growth opportunities that companies should pursue now and in the future?
• To stay relevant, what are the competitive differentiators that companies should employ in an increasingly crowded competitive base?
• What is the current patent landscape for this domain, and what are the key associated opportunities?
• What are the key game-changing disruptive technologies that might impact future market development?

Since its inception, CRISPR has gained strong traction from the global research community because of its huge potential in diverse applications. Considering CRISPR’s disruptive and game-changing applications, a number of large and small participants have invested in this domain. Along the same line, CRISPR has witnessed a multi-fold uptake in funding from the National Institutes of Health (NIH) and other government agencies. As a result, these investments have led to significant growth in new product and application development, thereby creating new market segments and revenue growth opportunities for existing companies and new entrants.

In 2017, the CRISPR/Cas9 tools market opportunity will likely be about $1.8 to $2 billion. The therapeutics and agriculture segments will contribute the most revenue potential. The market is currently highly fragmented, with a handful of global participants and a large number of application-focused participants operating in their respective segments. Competition in the therapeutics and agriculture domains is highly concentrated, and most market and technology developments have been focused around a few companies. Even large pharmaceutical companies have partnered with these existing participants to source innovation and to support their product development using CRISPR. With the ongoing patent war between the University of California and Broad Institute, this situation will likely remain the same. Frost & Sullivan expects that large pharmaceutical companies will only commit direct investments in this segment after understanding the final outcome of the ongoing patent cases.

The objective of this research study is to consider and analyze all these market developments and present a realistic market landscape. This research publication covers insights on existing and emerging growth opportunities in the CRISPR/Cas9 tools market. The study covers qualitative market insights on various market segments and sub-segments, including agriculture, human therapeutics, research tools, and drug discovery activities. The report identifies existing gaps in product and service offerings of key participants across segments, disruptive technologies, and key market and technology trends. The research study further delves into the market’s competitive landscape and patent licensing landscape analysis.

Key Questions This Study Will Answer:

Who are the key competitors in the emerging CRISPR/Cas9 market, both tools and therapeutics?

What are the growth opportunities that companies should pursue now and in the future?

To stay relevant, what are the competitive differentiators that companies should employ in an increasingly crowded competitive base?

What is the current patent landscape for this domain, and what are the key associated opportunities?

What are the key game-changing disruptive technologies that might impact future market development?